Korean Circulation Journal

The Korean Society of Cardiology (대한심장학회)
권호 표지
DOI QR코드

DOI QR Code

The Efficacy and Safety of High-Dose Intravenous Immunoglobulin in the Treatment of Kawasaki Disease: How Can We Predict Resistance to Intravenous Immunoglobulin Treatment of Kawasaki Disease?

  • Han, Ji Whan (Department of Pediatrics, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea)
  • Received : 2017.01.09
  • Accepted : 2017.02.24
  • Published : 2017.03.31
⟨ Previous Next ⟩

Abstract

Keywords

References

  1. Furusho K, Sato K, Soeda T, et al. High-dose intravenous gammaglobulin for Kawasaki disease. Lancet 1983;2:1359.
  2. Imbach P, Barandun S, d'Apuzzo V, et al. High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet 1981;1:1228-31.
  3. Burns JC, Franco A. The immunomodulatory effects of intravenous immunoglobulin therapy in Kawasaki disease. Expert Rev Clin Immunol 2015;11:819-25. https://doi.org/10.1586/1744666X.2015.1044980
  4. Negi VS, Elluru S, Siberil S, et al. Intravenous immunoglobulin: an update on the clinical use and mechanisms of action. J Clin Immunol 2007;27:233-45. https://doi.org/10.1007/s10875-007-9088-9
  5. Bayry J, Negi VS, Kaveri SV. Intravenous immunoglobulin therapy in rheumatic diseases. Nat Rev Rheumatol 2011;7:349-59. https://doi.org/10.1038/nrrheum.2011.61
  6. Schwab I, Nimmerjahn F. Intravenous immunoglobulin therapy: how does IgG modulate the immune system? Nat Rev Immunol 2013;13:176-89. https://doi.org/10.1038/nri3401
  7. Franco A, Touma R, Song Y, et al. Specificity of regulatory T cells that modulate vascular inflammation. Autoimmunity 2014;47:95-104. https://doi.org/10.3109/08916934.2013.860524
  8. Hsu CH, Chen MR, Hwang FY, et al. Efficacy of plasmin-treated intravenous gamma-globulin for therapy of Kawasaki syndrome. Pediatr Infect Dis J 1993;12:509-12. https://doi.org/10.1097/00006454-199306000-00010
  9. Harada K. Intravenous gamma-globulin treatment in Kawasaki disease. Acta paediatrica Japonica 1991;33:805-10. https://doi.org/10.1111/j.1442-200X.1991.tb02612.x
  10. Newburger JW, Takahashi M, Burns JC, et al. The treatment of Kawasaki syndrome with intravenous gamma globulin. N Engl J Med 1986;315:341-7. https://doi.org/10.1056/NEJM198608073150601
  11. Newburger JW, Takahashi M, Gerber MA, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the committee on rheumatic fever, endocarditis and Kawasaki disease, council on cardiovascular disease in the young, American heart association. Circulation 2004;110:2747-71. https://doi.org/10.1161/01.CIR.0000145143.19711.78
  12. Egami K, Muta H, Ishii M, et al. Prediction of resistance to intravenous immunoglobulin treatment in patients with Kawasaki disease. J Pediatr 2006;149:237-40. https://doi.org/10.1016/j.jpeds.2006.03.050
  13. Sano T, Kurotobi S, Matsuzaki K, et al. Prediction of nonresponsiveness to standard high-dose gamma-globulin therapy in patients with acute Kawasaki disease before starting initial treatment. Eur J Pediatr 2007;166:131-7.
  14. Kobayashi T, Inoue Y, Takeuchi K, et al. Prediction of intravenous immunoglobulin unresponsiveness in patients with Kawasaki disease. Circulation 2006;113:2606-12. https://doi.org/10.1161/CIRCULATIONAHA.105.592865
  15. Chang LS, Lo MH, Li SC, Yang MY, Hsieh KS, Kuo HC. The effect of $Fc{\gamma}RIIA$ and $Fc{\gamma}RIIB$ on coronary artery lesion formation and intravenous immunoglobulin treatment responses in children with Kawasaki disease. Oncotarget 2017;8:2044-52.
  16. Nagib D, Ana S, Anne F, et al. Natriuretic peptide as an adjunctive diagnostic test in the acute phase of Kawasaki disease. Pediatr Cardiol 2009;30:810-17 https://doi.org/10.1007/s00246-009-9441-2
  17. Eladawy M, Dominguez SR, Anderson MS, Glode MP. Abnormal liver panel in acute Kawasaki disease. Pediatr Infect Dis J 2011;30:141-4. https://doi.org/10.1097/INF.0b013e3181f6fe2a
  18. Lim GW, Lee M, Kim HS, Hong YM, Sohn S. Hyponatremia and syndrome of inappropriate antidiuretic hormone secretion in kawasaki disease. Korean Circ J 2010;40:507-13. https://doi.org/10.4070/kcj.2010.40.10.507
  19. Kim BY, Kim D, Kim YH, et al. Non-responders to intravenous immunoglobulin and coronary artery dilatation in Kawasaki disease: predictive parameters in Korean children. Korean Circ J 2016;46:542-9. https://doi.org/10.4070/kcj.2016.46.4.542
  20. Wang Y, Li Z, Hu G, et al. Unique molecular patterns uncovered in Kawasaki disease patients with elevated serum gamma glutamyl transferase levels: implications for intravenous immunoglobulin responsiveness. PLoS One 2016;11:e0167434. https://doi.org/10.1371/journal.pone.0167434
  21. Okuma Y, Suda K, Nakaoka H, et al. Serum tenascin-C as a novel predictor for risk of coronary artery lesion and resistance to intravenous immunoglobulin in Kawasaki disease- a multicenter retrospective study. Circ J 2016;80:2376-81. https://doi.org/10.1253/circj.CJ-16-0563
  22. Bonilla FA. Intravenous and subcutaneous immunoglobulin G replacement therapy. Allergy Asthma Proc 2016;37:426-31. https://doi.org/10.2500/aap.2016.37.3987
  23. Marie I, Cherin P, Michallet M, et al. Management of adverse effects related to human immunoglobulin therapy: Recommendations for clinical practice. Rev Med Interne 2016. [Epub ahead of print] doi:10.1016/j.revmed.2016.10.390.
  24. Katz U, Achiron A, Sherer Y, Shoenfeld Y. Safety of intravenous immunoglobulin (IVIG) therapy. Autoimmun Rev 2007;6:257-9. https://doi.org/10.1016/j.autrev.2006.08.011
  25. Hamrock DJ. Adverse events associated with intravenous immunoglobulin therapy. Int Immunopharmacol 2006;6:535-42. https://doi.org/10.1016/j.intimp.2005.11.015
  26. Radosevich M, Burnouf T. Intravenous immunoglobulin G: trends in production methods, quality control and quality assurance. Vox Sang 2010;98:12-28. https://doi.org/10.1111/j.1423-0410.2009.01226.x
  27. Stein MR, Wasserman RL, Moy J, et al. Efficacy, safety, and tolerability of IVIG-SN in patients with primary immunodeficiency. Lymphosign J 2015;2:21-9. https://doi.org/10.14785/lpsn-2014-0009
  28. Cohn EJ, Strong LE, Hughes WL, et al. Preparation and properties of serum and plasma proteins: a system for the separation into fractions of the protein and lipoprotein components of biological tissues and fluids. J Am Chem Soc 1946;68:459-75. https://doi.org/10.1021/ja01207a034
  29. Melin JL, Oncley M, Richert DA. The separation of the antibodies, isoagglutinins, prothrombin, plasminogen and beta-lipoprotein into subfractions of human plasma. J Am Chem Soc 1949;71:541-50. https://doi.org/10.1021/ja01170a048
  30. Yoon KL, Lee HY, Yu JJ, et al. Multicenter, single-arm, phase IV study to evaluate the efficacy and safety of the combined therapy of aspirin and high-dose "IVIG-SN" for pediatric patients with Kawasaki disease. Korean Circ J 2017;47:209-14. https://doi.org/10.4070/kcj.2016.0139
  31. Durongpisitkul K, Soongswang J, Laohaprasitiporn D, et al. Immunoglobulin failure and retreatment in Kawasaki disease. Pediatr Cardiol 2003;24:145-8. https://doi.org/10.1007/s00246-002-0216-2
  32. Clinically useful predictors of resistance to intravenous immunoglobulin and prognosis of coronary artery lesions in patients with incomplete Kawasaki disease. Korean Circ J 2014;44:328-35. https://doi.org/10.4070/kcj.2014.44.5.328
  33. Yeo Y, Kim T, Ha K, et al. Incomplete Kawasaki disease in patients younger than 1 year of age: a possible inherent risk factor. Eur J Pediatr 2009;168:157-62. https://doi.org/10.1007/s00431-008-0722-1

Cited by

  1. Bifidobacterium plays a protective role in TNF-α-induced inflammatory response in Caco-2 cell through NF-κB and p38MAPK pathways vol.464, pp.1, 2020, https://doi.org/10.1007/s11010-019-03651-3